The largest database of trusted experimental protocols

Surestep blood glucose meter

Manufactured by LifeScan
Sourced in United States

The SureStep blood glucose meter is a device used to measure the concentration of glucose in a person's blood. It provides a quick and accurate reading of the user's blood sugar level, allowing for effective diabetes management.

Automatically generated - may contain errors

12 protocols using surestep blood glucose meter

1

Subcutaneous Glucose Monitoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The iPro2 system (Medtronic Inc, Northridge, CA, USA) was used for subcutaneous interstitial glucose monitoring. The sensor (Enlite, Medtronic Inc) recorded glucose levels every 5 min for seven consecutive days, and was inserted on the first day and removed after 7 days, generating a daily record of 288 continuous sensor values. At least two capillary blood glucose readings per day were measured by using a Sure Step blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. TIR was defined as the percentage of time in the target glucose range of 3.9 to 10.0 mmol/L during the 7 days. Intraday glycemic variability (GV) parameters included the standard deviation (SD) of sensor glucose values, glucose coefficient of variation (CV), and mean amplitude of glycemic excursions (MAGE). CV was determined as SD divided by the mean glucose level. In addition, the arithmetic mean of the differences between consecutive nadirs and peaks was computed to determine the MAGE value. During the 7-day CGM period, all subjects adhered to the original therapy regimen and standard diet.
+ Open protocol
+ Expand
2

Intravenous Glucose Tolerance Test in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
After the animals were fasted for 8 h, their blood glucose levels were measured with a SureStep Blood Glucose meter (LifeScan, Milpitas, CA, USA). An intravenous glucose tolerance test (IVGTT) was performed by tail vein injection of 1 g/kg D-glucose (Sigma-Aldrich; Merck KGaA) on days 14 and 28. Plasma insulin levels were determined by using an ultrasensitive mouse insulin ELISA kit (cat. no. 80-INSMS-E01; ALPCO, Salem, NH, USA) and plasma glucagon levels were determined by using a glucagon ELISA kit (cat. no. 81518; Crystal Chem Inc., Downers Grove, IL, USA).
+ Open protocol
+ Expand
3

Continuous Glucose Monitoring in Standardized Diet

Check if the same lab product or an alternative is used in the 5 most similar protocols
A blinded CGM system (CGMS GOLD, Medtronic Inc, Northridge, CA, USA) was used for subcutaneous interstitial glucose monitoring. The sensor of the CGM system was inserted on the first day during hospital admission and removed after 72 h, generating a daily record of 288 continuous sensor values. At least 4 capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. Glucose coefficient of variation (CV) was calculated as the measure of GV. Time in range (TIR) was defined as the percentage of time in the target glucose range of 3.9 to 10.0 mmol/L during a 24-h period. Time above ranges [TARs; TAR > 140 mg/dL (TAR>140), TAR > 180 mg/dL (TAR>180), and TAR > 250 mg/dL (TAR>250)], and time below ranges [TBRs; TBR < 54 mg/dL (TBR<54), and TBR < 70 mg/dL (TBR<70)] were also ascertained. During the CGM period, all participants adhered to a standard diet, as previously reported (14 (link)).
+ Open protocol
+ Expand
4

Comprehensive Metabolic and Cardiovascular Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Body mass index (BMI) was calculated (kg/m2). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) taken three times using a sphygmomanometer and then averaged. Capillary glucose concentrations were measured with Lifescan Surestep blood glucose meter. Plasma glucose levels were measured using the glucose oxidase method. HbA1c was measured by high performance liquid chromatography (HPLC) with D-10 hemoglobin Testing Program (Bio-Rad). The serum insulin assay used magnetic beads-based enzymatic spectrofluorometric immunoassay with automatic enzyme immunoassay apparatus (AIA360, TOSOH). Serum glucose concentrations, total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC) were measured with Hitachi Model 7600 Series Automatic Analyzer.
+ Open protocol
+ Expand
5

Retrospective CGM Glucose Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols
Retrospective CGM systems (iPro 2; Medtronic Inc, Northridge, CA, USA) were used for subcutaneous interstitial glucose monitoring. All participants had the sensor inserted (Enlite; Medtronic Inc) on the first day of hospital admission and removed after 7 days, generating a daily record of 288 glucose values. At least four capillary blood glucose levels per day were measured using SureStep blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM systems. AUC for glucose >10.0 mmol/L, between 3.9 and 10.0 mmol/L, and <3.9 mmol/L were calculated according to the trapezoidal rule. AucIR was defined as the average percentage of AUC for glucose between 3.9 and 10.0 mmol/L, in the sum of AUC above, between and below these thresholds during a 24‐h period (Figure 1b). TIR was defined as the average percentage of time for glucose between 3.9 and 10 mmol/L during a 24‐h period. Glucose management indicator was calculated from the mean sensor glucose by the equation: glucose management indicator (%) = 3.31 + 0.023923 × mean glucose (mg/dL)14. Within‐day glycemic variability metrics including coefficient of variation, standard deviation (SD) and mean amplitude of glycemic excursions were also calculated. High blood glucose index and low blood glucose index were calculated to reflect the risk of hyperglycemia and hypoglycemia, respectively15.
+ Open protocol
+ Expand
6

Glucose Homeostasis in Fasted Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
After fasting for 8 h, blood glucose concentrations were measured by a Surestep Blood Glucose meter (Lifescan, Milpitas, CA, USA), and any blood glucose concentrations higher than 500 mg/dL were not included. IVGTTs were performed by tail vein injection of D-glucose (1 g/kg; Sigma) on days 7 and 14. After fasting for 8 h, plasma insulin concentrations were determined by using an ultrasensitive mouse insulin ELISA kit (Alpco, Salem, NH, USA), following the manufacturer’s instructions. After fasting for 8 h, plasma glucagon levels were determined by using a glucagon ELISA kit (Wako Pure Chemical Industries, Osaka, Japan).
+ Open protocol
+ Expand
7

Continuous Glucose Monitoring in Hospitalized Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
A CGM system (CGMS Gold; Medtronic Inc., Northridge, CA) was used for subcutaneous interstitial glucose monitoring, as previously described (10 (link)). In brief, the sensor of the CGM system was inserted on the first day during hospital admission (day 0) and removed after 72 h, generating a daily record of 288 continuous sensor values. At least four capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA) to calibrate the CGM system. TIR was defined as the percentage of time in the target glucose range of 3.9–10.0 mmol/L during a 24-h period. In addition, mean glucose and glucose coefficient of variation were calculated. During the 3-day CGM period, all participants adhered to a standard diet designed to ensure a total daily caloric intake of 25 kcal/kg/day, with 55% of calories coming from carbohydrates, 17% from proteins, and 28% from fats, as previously reported (10 (link)).
+ Open protocol
+ Expand
8

Longitudinal Study of Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood was collected weekly from tail veins, and blood glucose levels were measured using a validated one-touch basic glucose measurement system (SureStep blood glucose meter; LifeScan, USA). Body weight was also measured weekly from baseline. Food intake and water consumption of the control and STZ-treated groups were recorded twice a week at 09:00.
+ Open protocol
+ Expand
9

Comprehensive Metabolic Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Body mass index (BMI) was calculated (kg/m2). SBP and DBP were taken three times using a sphygmomanometer and then were averaged. Capillary glucose concentrations were measured with Lifescan Surestep blood glucose meter. Plasma glucose levels were measured using the glucose oxidase method. HbA1c was measured by high performance liquid chromatography(HPLC) with D-10 hemoglobin Testing Program (Bio-Rad). The serum insulin assay used magnetic beads-based enzymatic spectrofluorometric immunoassay with automatic enzyme immunoassay apparatus (AIA360, TOSOH). Serum glucose concentrations, total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDLC), low density lipoprotein cholesterol (LDLC), and serum creatinine(Scr) were measured with Hitachi Model 7600 Series Automatic Analyzer. Glomerular filtration rate(GFR) was estimated by using the reexpressed 4-variable Modification of Diet in Renal Disease (MDRD) Study equation (eGFR = 175 × (standardized Scr) –1.154 × age–0.203 × 0.742 [if female]) [22 (link)].
+ Open protocol
+ Expand
10

Continuous Glucose Monitoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
A retrospective CGM system (CGMS GOLD; Medtronic Inc., Northridge, CA, USA) was used for glucose monitoring, as previously described.[8 (link)] In brief, the sensor of the CGM system was inserted on day 0 and removed after 72 h, generating a daily record of 288 continuous sensor values. At least four capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. TIR was defined as the average percentage of time in the target glucose range of 70 to 180 mg/dL (3.9–10.0 mmol/L) during a 24 h period. TAR was defined as the average percentage of time above the target glucose range of 180 mg/dL (10.0 mmol/L). TBR was defined as the average percentage of time below the target glucose range of 70 mg/dL (3.9 mmol/L).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!